Multi-omics bioinformatic screening identifies PFDN2 as an obesity-correlated molecular target of triple-negative breast cancer

Abstract Triple-negative breast cancer (TNBC) is characterized by high malignancy, poor prognosis and a lack of specific therapeutic targets. Obesity acts as a major risk factor facilitating TNBC progression, while the molecular features underlying their correlation remain poorly systematically characterized. In this study, we integrated single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic datasets from the GEO database to screen candidate genes consistently changed in both obesity and TNBC. We constructed single-cell atlases, performed cell type annotation and analyzed intercellular communication networks using Seurat, SingleR and CellChat, respectively. PFDN2 was identified via intersection analysis of differentially expressed genes (DEGs). Functional experiments including qRT-PCR, siRNA transfection, CCK-8 and EDU proliferation assays verified that PFDN2 silencing markedly suppresses the proliferation of TNBC cells. Collectively, this study identified PFDN2 as a gene consistently changed both in obesity and TNBC. It provides novel insights into the molecular mechanisms of obesity-associated TNBC, and indicates that PFDN2 holds research potential as a molecular target and candidate therapeutic target.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-10-07
DOI
https://doi.org/10.1007/s12672-026-05994-y
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multi-omics bioinformatic screening identifies PFDN2 as an obesity-correlated molecular target of triple-negative breast cancer

Qingyu Song, Junpeng Huang, Huimin Liu
Discover Oncology
Breast Cancer Treatment Studies
article

Multi-omics bioinformatic screening identifies PFDN2 as an obesity-correlated molecular target of triple-negative breast cancer

Qingyu Song, Junpeng Huang, Huimin Liu
article en

Abstract

Abstract Triple-negative breast cancer (TNBC) is characterized by high malignancy, poor prognosis and a lack of specific therapeutic targets. Obesity acts as a major risk factor facilitating TNBC progression, while the molecular features underlying their correlation remain poorly systematically characterized. In this study, we integrated single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic datasets from the GEO database to screen candidate genes consistently changed in both obesity and TNBC. We constructed single-cell atlases, performed cell type annotation and analyzed intercellular communication networks using Seurat, SingleR and CellChat, respectively. PFDN2 was identified via intersection analysis of differentially expressed genes (DEGs). Functional experiments including qRT-PCR, siRNA transfection, CCK-8 and EDU proliferation assays verified that PFDN2 silencing markedly suppresses the proliferation of TNBC cells. Collectively, this study identified PFDN2 as a gene consistently changed both in obesity and TNBC. It provides novel insights into the molecular mechanisms of obesity-associated TNBC, and indicates that PFDN2 holds research potential as a molecular target and candidate therapeutic target.

Discover Oncology
Anqing City Hospital (CN)
Openalex Percentile: Top 17%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Multi-omics bioinformatic screening identifies PFDN2 as an obesity-correlated molecular target of triple-negative breast cancer — Qingyu Song, Junpeng Huang, et al. · Discover Oncology (2026) | TGRS Research Map | TGRS